Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NYSE:CBM's Cash to Debt is ranked higher than
99% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NYSE:CBM: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NYSE:CBM' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.25 Max: No Debt
Current: No Debt
Equity to Asset 0.66
NYSE:CBM's Equity to Asset is ranked lower than
51% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NYSE:CBM: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:CBM' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.44 Max: 0.74
Current: 0.66
0.22
0.74
Interest Coverage 244.15
NYSE:CBM's Interest Coverage is ranked lower than
69% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NYSE:CBM: 244.15 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:CBM' s Interest Coverage Range Over the Past 10 Years
Min: 1.97  Med: 14.64 Max: No Debt
Current: 244.15
F-Score: 7
Z-Score: 7.84
M-Score: -2.89
WACC vs ROIC
19.53%
24.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 21.92
NYSE:CBM's Operating margin (%) is ranked higher than
88% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NYSE:CBM: 21.92 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:CBM' s Operating margin (%) Range Over the Past 10 Years
Min: -2.77  Med: 10.34 Max: 21.92
Current: 21.92
-2.77
21.92
Net-margin (%) 13.24
NYSE:CBM's Net-margin (%) is ranked higher than
85% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NYSE:CBM: 13.24 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:CBM' s Net-margin (%) Range Over the Past 10 Years
Min: -98.33  Med: 6.29 Max: 82.87
Current: 13.24
-98.33
82.87
ROE (%) 18.79
NYSE:CBM's ROE (%) is ranked higher than
92% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NYSE:CBM: 18.79 )
Ranked among companies with meaningful ROE (%) only.
NYSE:CBM' s ROE (%) Range Over the Past 10 Years
Min: -94.37  Med: 12.78 Max: 120.02
Current: 18.79
-94.37
120.02
ROA (%) 11.71
NYSE:CBM's ROA (%) is ranked higher than
92% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NYSE:CBM: 11.71 )
Ranked among companies with meaningful ROA (%) only.
NYSE:CBM' s ROA (%) Range Over the Past 10 Years
Min: -37.93  Med: 4.64 Max: 42.71
Current: 11.71
-37.93
42.71
ROC (Joel Greenblatt) (%) 33.84
NYSE:CBM's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NYSE:CBM: 33.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:CBM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1.19  Med: 12.91 Max: 33.84
Current: 33.84
-1.19
33.84
Revenue Growth (3Y)(%) 13.40
NYSE:CBM's Revenue Growth (3Y)(%) is ranked higher than
65% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NYSE:CBM: 13.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:CBM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.1  Med: 0.3 Max: 13.4
Current: 13.4
-18.1
13.4
EBITDA Growth (3Y)(%) 22.30
NYSE:CBM's EBITDA Growth (3Y)(%) is ranked higher than
75% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NYSE:CBM: 22.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:CBM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.2  Med: 0.1 Max: 33.1
Current: 22.3
-27.2
33.1
EPS Growth (3Y)(%) -5.60
NYSE:CBM's EPS Growth (3Y)(%) is ranked lower than
52% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NYSE:CBM: -5.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:CBM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.5  Med: 7.8 Max: 79.7
Current: -5.6
-21.5
79.7
» NYSE:CBM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CBM Guru Trades in Q4 2015

Jim Simons 319,200 sh (-8.30%)
Joel Greenblatt 110,565 sh (-19.35%)
Chuck Royce 201,500 sh (-40.30%)
Paul Tudor Jones 6,000 sh (-71.39%)
» More
Q1 2016

CBM Guru Trades in Q1 2016

Third Avenue Management 76,681 sh (New)
Columbia Wanger 287,570 sh (New)
Paul Tudor Jones 7,400 sh (+23.33%)
Chuck Royce 203,298 sh (+0.89%)
Joel Greenblatt Sold Out
Jim Simons 162,300 sh (-49.15%)
» More
Q2 2016

CBM Guru Trades in Q2 2016

Steven Cohen 111,900 sh (New)
RS Investment Management 84,110 sh (New)
Columbia Wanger 314,909 sh (+9.51%)
Third Avenue Management 76,681 sh (unchged)
Paul Tudor Jones 7,164 sh (-3.19%)
Chuck Royce 170,598 sh (-16.08%)
Jim Simons 34,300 sh (-78.87%)
» More
Q3 2016

CBM Guru Trades in Q3 2016

Third Avenue Management 83,939 sh (+9.47%)
Steven Cohen 113,400 sh (+1.34%)
Jim Simons Sold Out
Paul Tudor Jones 6,734 sh (-6.00%)
Columbia Wanger 190,786 sh (-39.42%)
Chuck Royce 68,098 sh (-60.08%)
» More
» Details

Insider Trades

Latest Guru Trades with CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:AVXS, NAS:TBPH, NAS:HALO, NAS:FPRX, NYSE:PBYI, NAS:LXRX, NAS:ARIA, NAS:ONCE, NAS:FGEN, NAS:AAAP, NAS:DBVT, NAS:CLVS, OTCPK:GENSF, NAS:XLRN, NYSE:AXON, NAS:OPHT, NAS:ARRY, NAS:SAGE, NAS:ALDR, NAS:FOLD » details
Traded in other countries:XBX.Germany,
Cambrex Corp is a life sciences company. It provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics.

Cambrex Corp was incorporated as a Delaware corporation in 1981 and began business in December 1981. It is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company supplies its products and services to innovator and generic pharmaceutical companies. The Company has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company participates in markets that serve the healthcare industry. Its customers include generic drug companies and companies that discover and commercialize new small molecule human therapeutics using organic chemistry. The Company uses its technical expertise in chemical processes to meet the needs of its customers for high quality products and services for specialized applications. The Company's business is comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The products and services are supplied globally to innovator and generic drug companies. Its products include APIs, pharmaceutical intermediates and other fine chemicals. The Company's products and services are sold to a diverse group of several hundred customers, with one customer, Gilead Sciences, Inc. The Company owns 22 issued patents and has 3 patent applications pending in the United States and owns over 190 patents and has over 100 patent applications pending in foreign countries covering various technologies. The manufacturing of pharmaceutical products is subject to extensive regulation by governmental authorities, including the FDA, the European Medicines Agency and comparable regulatory authorities in other countries.

Guru Investment Theses on Cambrex Corp

Third Avenue Comments on Cambrex Corp - May 27, 2016

Cambrex Corp. (NYSE:CBM) We took advantage of the February sell off in the market to acquire shares of Cambrex at around $38 per share, an attractive discount to our estimate of NAV. We see the combination of a strong balance sheet and a healthy revenue outlook as supportive for book value growth to continue, given the dynamics of Cambrex's business.


Cambrex is a well-financed specialty chemical company focused on life sciences; it develops and commercializes active pharmaceutical ingredients (APIs). Cambrex also produces Generic APIs, Controlled Substance APIs and is expanding into finished-dosage generic API manufacturing. Cambrex's API business is unique in that it manufactures the active ingredient in several leading pharmaceuticals and serves as a supplier to various drug companies. As such, it generates revenues from volumes sold and not price per finished pill. Cambrex's customers focus not only on product purity but also on quality, consistency and documentation of the manufacturing process ascompetitive attributes.


Several long-term drivers support revenue growth for Cambrex.



  1. Cambrex is a substantial beneficiary of the U.S. Federal Drug Administration's (FDA) significantly enhanced effort to ensure quality manufacturing processes. The company has benefitted as larger pharmaceutical companies have re-shored their API sourcing activities to "Western" Current Good Manufacturing Practice (CGMP) companies.

  2. Industry growth remains healthy, aided by the increasing number of small molecule drug developments and pending regulatory approvals in the U.S. and Europe.

  3. Pharmaceutical companies are continuing to reduce their own manufacturing activities and thus turning to outsourcing firms, such as Cambrex, to focus on new drug development.

Cambrex is in the midst of a capacity expansion in Charles City, Iowa that should drive significant revenue growth as this capacity is completed and filled for the next few years.



From Chip Rewey's second quarter 2016 Third Avenue Small-Cap Value Fund letter.



Check out Martin Whitman,Third Avenue Management latest stock trades

Top Ranked Articles about Cambrex Corp

Third Avenue Comments on Cambrex Corp Guru stock highlight
Cambrex Corp. (NYSE:CBM) We took advantage of the February sell off in the market to acquire shares of Cambrex at around $38 per share, an attractive discount to our estimate of NAV. We see the combination of a strong balance sheet and a healthy revenue outlook as supportive for book value growth to continue, given the dynamics of Cambrex's business.

Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.29
CBM's P/E(ttm) is ranked higher than
51% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. CBM: 28.29 )
Ranked among companies with meaningful P/E(ttm) only.
CBM' s P/E(ttm) Range Over the Past 10 Years
Min: 1.05  Med: 15.59 Max: 59.25
Current: 28.29
1.05
59.25
PE(NRI) 26.08
CBM's PE(NRI) is ranked higher than
54% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. CBM: 26.08 )
Ranked among companies with meaningful PE(NRI) only.
CBM' s PE(NRI) Range Over the Past 10 Years
Min: 5.27  Med: 16.35 Max: 94.8
Current: 26.08
5.27
94.8
Price/Owner Earnings (ttm) 33.60
CBM's Price/Owner Earnings (ttm) is ranked lower than
54% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.19 vs. CBM: 33.60 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CBM' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.28  Med: 18.45 Max: 364.38
Current: 33.6
1.28
364.38
P/B 4.68
CBM's P/B is ranked lower than
59% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CBM: 4.68 )
Ranked among companies with meaningful P/B only.
CBM' s P/B Range Over the Past 10 Years
Min: 0.61  Med: 2.23 Max: 5.9
Current: 4.68
0.61
5.9
P/S 3.74
CBM's P/S is ranked higher than
76% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. CBM: 3.74 )
Ranked among companies with meaningful P/S only.
CBM' s P/S Range Over the Past 10 Years
Min: 0.18  Med: 1.36 Max: 10.86
Current: 3.74
0.18
10.86
PFCF 31.90
CBM's PFCF is ranked lower than
58% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. CBM: 31.90 )
Ranked among companies with meaningful PFCF only.
CBM' s PFCF Range Over the Past 10 Years
Min: 4.86  Med: 16.29 Max: 276
Current: 31.9
4.86
276
POCF 15.18
CBM's POCF is ranked higher than
59% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. CBM: 15.18 )
Ranked among companies with meaningful POCF only.
CBM' s POCF Range Over the Past 10 Years
Min: 2.91  Med: 10.88 Max: 367.92
Current: 15.18
2.91
367.92
EV-to-EBIT 15.71
CBM's EV-to-EBIT is ranked higher than
59% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. CBM: 15.71 )
Ranked among companies with meaningful EV-to-EBIT only.
CBM' s EV-to-EBIT Range Over the Past 10 Years
Min: -118.8  Med: 11.65 Max: 306.6
Current: 15.71
-118.8
306.6
EV-to-EBITDA 12.85
CBM's EV-to-EBITDA is ranked higher than
60% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. CBM: 12.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.8  Med: 7.8 Max: 35.9
Current: 12.85
-0.8
35.9
PEG 1.35
CBM's PEG is ranked higher than
63% of the 95 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. CBM: 1.35 )
Ranked among companies with meaningful PEG only.
CBM' s PEG Range Over the Past 10 Years
Min: 0.48  Med: 1.25 Max: 6.81
Current: 1.35
0.48
6.81
Shiller P/E 31.08
CBM's Shiller P/E is ranked higher than
67% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 48.79 vs. CBM: 31.08 )
Ranked among companies with meaningful Shiller P/E only.
CBM' s Shiller P/E Range Over the Past 10 Years
Min: 2.83  Med: 29.33 Max: 435.33
Current: 31.08
2.83
435.33
Current Ratio 3.66
CBM's Current Ratio is ranked lower than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CBM: 3.66 )
Ranked among companies with meaningful Current Ratio only.
CBM' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.61 Max: 5.19
Current: 3.66
0.9
5.19
Quick Ratio 1.84
CBM's Quick Ratio is ranked lower than
72% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. CBM: 1.84 )
Ranked among companies with meaningful Quick Ratio only.
CBM' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.44 Max: 4.55
Current: 1.84
0.5
4.55
Days Inventory 172.58
CBM's Days Inventory is ranked lower than
63% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. CBM: 172.58 )
Ranked among companies with meaningful Days Inventory only.
CBM' s Days Inventory Range Over the Past 10 Years
Min: 124.14  Med: 131.78 Max: 172.58
Current: 172.58
124.14
172.58
Days Sales Outstanding 29.57
CBM's Days Sales Outstanding is ranked higher than
76% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. CBM: 29.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.57  Med: 61.31 Max: 81.77
Current: 29.57
29.57
81.77
Days Payable 48.35
CBM's Days Payable is ranked lower than
55% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. CBM: 48.35 )
Ranked among companies with meaningful Days Payable only.
CBM' s Days Payable Range Over the Past 10 Years
Min: 37.86  Med: 51.72 Max: 69.01
Current: 48.35
37.86
69.01

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
CBM's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CBM: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.1  Med: -1.6 Max: -0.1
Current: -2.1
-4.1
-0.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 16.77
CBM's Price/Net Current Asset Value is ranked lower than
81% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. CBM: 16.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CBM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.42  Med: 18.88 Max: 107.17
Current: 16.77
2.42
107.17
Price/Tangible Book 5.18
CBM's Price/Tangible Book is ranked lower than
56% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CBM: 5.18 )
Ranked among companies with meaningful Price/Tangible Book only.
CBM' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 4.04 Max: 14.12
Current: 5.18
1.62
14.12
Price/Projected FCF 2.44
CBM's Price/Projected FCF is ranked higher than
58% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. CBM: 2.44 )
Ranked among companies with meaningful Price/Projected FCF only.
CBM' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.83  Med: 2.21 Max: 12.66
Current: 2.44
0.83
12.66
Price/Median PS Value 2.71
CBM's Price/Median PS Value is ranked lower than
88% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CBM: 2.71 )
Ranked among companies with meaningful Price/Median PS Value only.
CBM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 1.14 Max: 6.93
Current: 2.71
0.2
6.93
Price/Peter Lynch Fair Value 1.33
CBM's Price/Peter Lynch Fair Value is ranked higher than
62% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. CBM: 1.33 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CBM' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.57  Med: 1.21 Max: 8.25
Current: 1.33
0.57
8.25
Price/Graham Number 2.44
CBM's Price/Graham Number is ranked higher than
51% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. CBM: 2.44 )
Ranked among companies with meaningful Price/Graham Number only.
CBM' s Price/Graham Number Range Over the Past 10 Years
Min: 0.8  Med: 1.79 Max: 4.29
Current: 2.44
0.8
4.29
Earnings Yield (Greenblatt) (%) 6.41
CBM's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. CBM: 6.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CBM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 8.3 Max: 209.9
Current: 6.41
0.3
209.9
Forward Rate of Return (Yacktman) (%) 21.29
CBM's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.80 vs. CBM: 21.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CBM' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -35.3  Med: 7.25 Max: 21.8
Current: 21.29
-35.3
21.8

More Statistics

Revenue (TTM) (Mil) $469.0
EPS (TTM) $ 1.88
Beta2.36
Short Percentage of Float3.95%
52-Week Range $29.50 - 59.41
Shares Outstanding (Mil)32.15

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) 2.49
EPS w/o NRI ($) 2.49
EPS Growth Rate
(3Y to 5Y Estimate)
8.00%
Dividends Per Share ($)
» More Articles for CBM

Headlines

Articles On GuruFocus.com
Third Avenue Comments on Cambrex Corp May 27 2016 
Chip Rewey's Third Avenue Small-Cap Value Fund 2nd Quarter Commentary May 27 2016 
Royce Smaller-Companies Growth Fund Annual Letter Mar 19 2016 
Royce Smaller-Companies Growth Fund Shareholder Letter Sep 20 2015 
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
Zacks.com featured highlights: Big 5 Sporting Goods, Cambrex and Children's Place Dec 07 2016
Zacks.com featured highlights: Stamps.com, Gibraltar Industries, FutureFuel and Cambrex Dec 07 2016
AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting Dec 07 2016
Sage Therapeutics Stock Up on SAGE-547 Regulatory Update Dec 07 2016
Juno Reports Positive Phase I Study Data on Lymphoma Drug Dec 06 2016
Novo Nordisk Files Regulatory Application for Semaglutide Dec 06 2016
Alnylam Reports Positive Data on Fitusiran, Givosiran Dec 05 2016
Pfizer (PFE) Presents Favorable Data on Leukemia Candidate Dec 05 2016
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data Dec 05 2016
Merck KGaA (MKGAF) Expands Distribution Deal with Roche Dec 02 2016
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S. Dec 01 2016
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors Dec 01 2016
CAMBREX CORP Financials Nov 30 2016
Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile Nov 30 2016
Zacks.com featured highlights: Forestar Real Estate Group, McDermott International, Coherent,... Nov 30 2016
Zacks.com featured highlights: Alliance Resource Partners, EnerSys, Cambrex and Children's Place Nov 29 2016
Zacks.com featured highlights: Edgewell Personal Care, Cambrex, Humana, Research Frontiers and... Nov 29 2016
Hedge Funds Are Buying Cambrex Corporation (CBM) Nov 28 2016
Bet on These 4 Top Stocks with Upgraded Broker Ratings Nov 28 2016
Glaxo (GSK) Files Regulatory Application for Shingrix in EU Nov 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)